Liz Carmouche was practically on fire when I met her at the Cannabis World Congress and Business Expo (CWCBExpo) at the Javits Center in Manhattan a few weeks ago.
For those of you who don't follow mixed martial arts, she's one of the top fighters in the Ultimate Fighting Championship (UFC). She went for nearly five minutes against the legendary bantamweight Ronda Rousey in the UFC's first-ever female fight - and she won the first MMA fight ever held in the famed Madison Square Garden.
But Carmouche was not at CWCBExpo to promote her UFC career.
She was there as a promoter and proud user of products from HempMeds, a small company specializing in cannabidiol (CBD) products.
Formerly opposed to the use of any cannabis-based products, Carmouche is now a fierce advocate for CBD.
She could make a cannabis believer out of anyone. Here's what she had to say...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.